United States HR 4244: MAGIC Act

Status: Referred to the Subcommittee on Health. (as of 2019-09-10)

State: United States · Session: 116 · Bill: HR 4244

Subjects: Competition and antitrust, Digestive and metabolic diseases, Drug safety, medical device, and laboratory regulation, Licensing and registrations, Manufacturing, Prescription drugs

Sponsors: Mike Kelly, Brian K. Fitzpatrick, Fred Keller, Glenn Thompson, Scott Perry

Bill Text

I
116TH CONGRESS
1ST SESSION H. R. 4244
To provide for a pathway for chemically synthesized insulin to be approved
under an abbreviated new drug application submitted under the Federal
Food, Drug, and Cosmetic Act, and for other purposes.
IN THE HOUSE OF REPRESENTATIVES
SEPTEMBER 9, 2019
Mr. KELLY of Pennsylvania introduced the following bill; which was referred
to the Committee on Energy and Commerce
A BILL
To provide for a pathway for chemically synthesized insulin
to be approved under an abbreviated new drug applica-
tion submitted under the Federal Food, Drug, and Cos-
metic Act, and for other purposes.
Be it enacted by the Senate and House of Representa-1
tives of the United States of America in Congress assembled, 2
SECTION 1. SHORT TITLE. 3
This Act may be cited as the ‘‘Market Access for Ge-4
neric Insulin Competition’’ or the ‘‘MAGIC Act’’. 5
VerDate Sep 11 2014 01:11 Sep 10, 2019 Jkt 089200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\H4244.IH H4244kjohnson on DSK79L0C42 with BILLS

2
•HR 4244 IH
SEC. 2. PROVIDING FOR A PATHWAY FOR APPROVAL OF 1
CHEMICALLY SYNTHESIZED INSULIN UNDER 2
AN ABBREVIATED NEW DRUG APPLICATION. 3
(a) IN GENERAL.—Section 7002(e)(2) of the Patient 4
Protection and Affordable Care Act (42 U.S.C. 262 note) 5
is amended— 6
(1) in subparagraph (B), by redesignating 7
clauses (i) and (ii) as subclauses (I) and (II), respec-8
tively, and moving the margins of such subclauses 9
(as so redesignated) two ems to the right; 10
(2) in subparagraph (A), by striking ‘‘such bio-11
logical product’’ and inserting ‘‘(i) such biological 12
product’’; 13
(3) by redesignating subparagraph (B) as 14
clause (ii) and moving the margin of such clause (as 15
so redesignated) two ems to the right; 16
(4) in clause (ii) (as so redesignated), by strik-17
ing the period at the end and inserting ‘‘; or’’; and 18
(5) by adding at the end the following: 19
‘‘(B) notwithstanding paragraphs (3) and 20
(4), the application is submitted under sub-21
section (j) of such section for chemically syn-22
thesized insulin or any analogue of chemically 23
synthesized insulin for which the listed drug is 24
a biological product that is, pursuant to para-25
VerDate Sep 11 2014 01:11 Sep 10, 2019 Jkt 089200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\H4244.IH H4244kjohnson on DSK79L0C42 with BILLS

3
•HR 4244 IH
graph (4), deemed to be licensed under section 1
351 of the Public Health Service Act.’’. 2
(b) EFFECTIVE DATE.—The amendments made by 3
this section shall apply with respect to applications sub-4
mitted on or after January 1, 2020. 5
Æ
VerDate Sep 11 2014 01:11 Sep 10, 2019 Jkt 089200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6301 E:\BILLS\H4244.IH H4244kjohnson on DSK79L0C42 with BILLS

View United States HR 4244 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.